Added to YB: 2025-10-27
Pitch date: 2025-10-26
IDXG [bullish]
Interpace Biosciences, Inc.
+49.8%
current return
Author Info
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
Market Cap
$44.0M
Pitch Price
$1.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.33
P/E
1.83
EV/Sales
1.17
Sector
Health Care Providers and Services
Category
turnaround
Trading at 7x Estimated Earnings Post-Restructuring
IDXG: Post-restructuring thyroid diagnostics play at ~7x est earnings, 0.72x EV/Rev vs peers VCYT/MDxH at 2.5-4x. PancraGEN loss dropped stock -70% to $0.93. Q3 catalyst: SG&A cuts reveal ~$4-6M EBIT power on $35M rev, 16% vol growth taking share. Kamin involved. Risks: illiquid ($6k/day), CLFS reimbursement reset 2026, going dark. 100%+ upside at 1.5x EV/Rev.
Read full article (8 min)